Gastroesophageal junction adenocarcinoma Trials in Taipei, Taiwan
Conditions / Gastroesophageal junction adenocarcinoma / Taipei, Taiwan
Clinical trials for Gastroesophageal junction adenocarcinoma investigate a range of treatment strategies and patient populations.
17 total trials for this combination
Showing top 10 of 17 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04032704 | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | TERMINATED | PHASE2 |
| NCT06157892 | A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors | RECRUITING | PHASE2 |
| NCT05111626 | Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT04389632 | A Study of Sigvotatug Vedotin in Advanced Solid Tumors | RECRUITING | PHASE1 |
| NCT02572687 | A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies | COMPLETED | PHASE1 |
| NCT06764875 | A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer | RECRUITING | PHASE3 |
| NCT05002127 | A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) | ACTIVE_NOT_RECRUITING | PHASE2/PHASE3 |
| NCT07431281 | Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 | RECRUITING | PHASE3 |
| NCT05052801 | Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT03175224 | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors | RECRUITING | PHASE2 |